# DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

> **NCT06645236** · NA · RECRUITING · sponsor: **QIAGEN Gaithersburg, Inc** · enrollment: 600 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DEVICE:** therascreen® KRAS RGQ PCR Kit

## Key facts

- **NCT ID:** NCT06645236
- **Lead sponsor:** QIAGEN Gaithersburg, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-22
- **Primary completion:** 2030-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06645236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06645236, "DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06645236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*